EMC92-ISS Superior to Other Current Markers in Risk Classification for Myeloma Survival

Share this content:
The EMC92-International Staging System is a robust novel prognostic tool compared with current markers.
The EMC92-International Staging System is a robust novel prognostic tool compared with current markers.

Investigators have shown that the EMC92-International Staging System (ISS) is a robust novel prognostic tool compared with current markers, according to an online article published ahead of print in Blood.1

Patients with multiple myeloma require reliable prognostic and predictive scoring systems. Currently, clinical and biological risk factors are used independently.

In this study, ISS, FISH markers, and gene expression (GEP) classifiers were combined in order to identify novel risk classifications in a discovery/validation setting. Several datasets were used on 4,750 patients.

RELATED: In Heavily Pretreated Refractory Myeloma, Daratumumab May Be Safe, Effective

Twenty risk markers were evaluated including t(4; 14) and deletion of 17p (FISH), EMC92, GEP classifiers, and ISS.

The novel risk classifications showed that ISS is a valuable partner to FISH and, when ranked against all novel and existing risk classifications, the EMC92-ISS combination is the strongest predictor of overall survival.

Median survival was 24 months for the highest risk group, 47 and 61 months for the intermediate risk group, and a median was not reached after 96 months for the lowest risk group.

Reference

  1. Kuiper R, van Duin M, van Vilet M, et al. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System [published online ahead of print September 1, 2015]. Blood. doi: 10.1182/blood-2015-05-644039.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters